Summit Tx Capital, L.P. Arvinas, Inc. Transaction History
Summit Tx Capital, L.P.
- $2.32 Trillion
- Q1 2025
A detailed history of Summit Tx Capital, L.P. transactions in Arvinas, Inc. stock. As of the latest transaction made, Summit Tx Capital, L.P. holds 14,195 shares of ARVN stock, worth $88,860. This represents 0.0% of its overall portfolio holdings.
Number of Shares
14,195Holding current value
$88,860% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding ARVN
# of Institutions
242Shares Held
59.2MCall Options Held
2.65MPut Options Held
1.1M-
Vanguard Group Inc Valley Forge, PA8.36MShares$52.3 Million0.0% of portfolio
-
Black Rock Inc. New York, NY6.26MShares$39.2 Million0.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il3.88MShares$24.3 Million0.01% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.83MShares$23.9 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY3.33MShares$20.9 Million0.38% of portfolio
About ARVINAS, INC.
- Ticker ARVN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 53,205,300
- Market Cap $333M
- Description
- Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...